Celularity Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
CELU Nasdaq 2830 www.celularity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celularity Inc.

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner - Sep 30th, 2026 9:57 am
Celularity Announces Naveen Jain to Join Board of Directors - Sep 29th, 2026 6:30 am
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements - Sep 24th, 2026 7:15 am
Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity - Aug 27th, 2026 8:27 am
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform - Aug 27th, 2026 7:00 am
Celularity Provides Update Regarding Nasdaq Listing Compliance - Aug 25th, 2026 5:59 pm
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE - Aug 20th, 2026 2:05 pm
NexGel Files to Register 15.25 Million Shares From Note Conversions - Aug 20th, 2026 11:35 am
NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp - Aug 17th, 2026 8:54 am
NEXGEL Reports Second Quarter 2026 Financial Results - Aug 17th, 2026 6:00 am
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - Jun 4th, 2026 6:00 am
Celularity Releases CEO Letter to Shareholders - Jun 3rd, 2026 2:15 pm
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - Jun 3rd, 2026 6:00 am
Celularity Receives Nasdaq Notice Regarding Form 10-Q - May 29th, 2026 3:15 pm
NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of Directors - May 6th, 2026 7:00 am
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - May 1st, 2026 2:30 pm
NEXGEL Appoints Ian Blackman as Chief Financial Officer - Apr 27th, 2026 7:00 am
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment - Apr 21st, 2026 7:00 am
NEXGEL, Inc. Q4 2025 Earnings Call Summary - Apr 21st, 2026 6:30 am
Celularity Announces Closing of Transaction with NexGel - Apr 21st, 2026 6:30 am